[go: up one dir, main page]

RU2000116633A - Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, и способ их получения, промежуточные соединения, фармацевтическая композиция - Google Patents

Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, и способ их получения, промежуточные соединения, фармацевтическая композиция

Info

Publication number
RU2000116633A
RU2000116633A RU2000116633/04A RU2000116633A RU2000116633A RU 2000116633 A RU2000116633 A RU 2000116633A RU 2000116633/04 A RU2000116633/04 A RU 2000116633/04A RU 2000116633 A RU2000116633 A RU 2000116633A RU 2000116633 A RU2000116633 A RU 2000116633A
Authority
RU
Russia
Prior art keywords
pharnesyl
transferase
producing
respect
pharmaceutical composition
Prior art date
Application number
RU2000116633/04A
Other languages
English (en)
Other versions
RU2179975C1 (ru
Inventor
Хиун Ил ЛИ (KR)
Хиун Ил ЛИ
Дзонг Сунг КОХ (KR)
Дзонг Сунг Кох
Дзин Хо ЛИ (KR)
Дзин Хо ЛИ
Вон Хи ДЗУНГ (KR)
Вон Хи ДЗУНГ
Ю Сеунг ШИН (KR)
Ю Сеунг ШИН
Хиун Хо ЧУНГ (KR)
Хиун Хо ЧУНГ
Дзонг Хиун КИМ (KR)
Дзонг Хиун КИМ
Сеонг Гу РО (KR)
Сеонг Гу РО
Тае Саенг ЧОЙ (KR)
Тае Саенг ЧОЙ
Шин Ву ДЗЕОНГ (KR)
Шин Ву ДЗЕОНГ
Тае Хван КВАК (KR)
Тае Хван КВАК
Ин Ае АХН (KR)
Ин Ае Ахн
Хиун Сунг КИМ (KR)
Хиун Сунг КИМ
Сун Хва ЛИ (KR)
Сун Хва ЛИ
Кви Хва КИМ (KR)
Кви Хва КИМ
Дзунг Квон ЙОО (KR)
Дзунг Квон ЙОО
Original Assignee
Эл Джи Кемикал Лтд. (KR)
Эл Джи Кемикал Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980011359A external-priority patent/KR19990066679A/ko
Priority claimed from KR1019980023698A external-priority patent/KR20000002788A/ko
Priority claimed from KR1019980046457A external-priority patent/KR20000015758A/ko
Application filed by Эл Джи Кемикал Лтд. (KR), Эл Джи Кемикал Лтд. filed Critical Эл Джи Кемикал Лтд. (KR)
Application granted granted Critical
Publication of RU2179975C1 publication Critical patent/RU2179975C1/ru
Publication of RU2000116633A publication Critical patent/RU2000116633A/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Claims (1)

  1. Текст формулы в факсимильном виде (см. графическую часть).
RU2000116633/04A 1997-11-28 1998-11-25 Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, способ их получения, промежуточные соединения, фармацевтическая композиция RU2179975C1 (ru)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
KR19970063858 1997-11-28
KR1997/63858 1997-11-28
KR1019980011359A KR19990066679A (ko) 1997-11-28 1998-03-31 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR1998/11359 1998-03-31
KR1998/23698 1998-06-23
KR1019980023698A KR20000002788A (ko) 1998-06-23 1998-06-23 피라졸 구조를 갖는 파네실 전이효소 억제제 및그의 제조방법
KR1998/24423 1998-06-26
KR1019980024423A KR19990062439A (ko) 1997-11-28 1998-06-26 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR19980031512 1998-08-03
KR1998/31512 1998-08-03
KR1019980046457A KR20000015758A (ko) 1998-08-03 1998-10-30 피롤 구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
KR1998/46457 1998-10-30

Publications (2)

Publication Number Publication Date
RU2179975C1 RU2179975C1 (ru) 2002-02-27
RU2000116633A true RU2000116633A (ru) 2004-02-20

Family

ID=27555104

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000116633/04A RU2179975C1 (ru) 1997-11-28 1998-11-25 Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, способ их получения, промежуточные соединения, фармацевтическая композиция

Country Status (18)

Country Link
US (3) US6268363B1 (ru)
EP (1) EP1045846B1 (ru)
JP (2) JP3548118B2 (ru)
CN (1) CN1188407C (ru)
AR (1) AR017700A1 (ru)
AT (1) ATE239014T1 (ru)
AU (1) AU731272B2 (ru)
BR (1) BR9815423A (ru)
CA (1) CA2310629A1 (ru)
DE (1) DE69814167T2 (ru)
ES (1) ES2193590T3 (ru)
HU (1) HUP0004238A3 (ru)
ID (1) ID24175A (ru)
IL (1) IL135473A0 (ru)
NZ (1) NZ504013A (ru)
PL (1) PL340729A1 (ru)
RU (1) RU2179975C1 (ru)
WO (1) WO1999028315A1 (ru)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69904302T2 (de) * 1998-02-02 2003-08-14 Lg Chemical Ltd., Seoul/Soul Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
KR100395300B1 (ko) * 1999-08-11 2003-08-27 주식회사 엘지생명과학 피롤구조를 갖는 파네실 전이효소 억제제 및 그의 제조방법
CN1151148C (zh) * 1999-04-13 2004-05-26 Lgci株式会社 具有吡咯结构的法尼转移酶抑制剂及其制备方法
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
KR100412334B1 (ko) * 2000-02-22 2003-12-31 주식회사 엘지생명과학 4-치환된-1ｈ-피롤-3-카복실산 에스테르의 새로운 제조방법
AU2001244596A1 (en) * 2000-03-30 2001-10-15 Rei Asakai Indolylpyrrole derivatives and cell death inhibitors
AU2003237121A1 (en) * 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
RU2462463C2 (ru) * 2002-08-23 2012-09-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4585448B2 (ja) * 2002-12-23 2010-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 第Ｘａ因子阻害剤としてのピラゾール−誘導体
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
CN1819996B (zh) * 2003-07-10 2010-10-27 Osi制药公司 作为细胞色素p450抑制剂的亚萘基衍生物
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
US7214825B2 (en) 2003-10-17 2007-05-08 Honeywell International Inc. O-(3-chloropropenyl) hydroxylamine free base
US7880017B2 (en) 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US7183305B2 (en) 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
US20080119456A1 (en) * 2004-05-29 2008-05-22 Trond Ulven Substituted Thiazoleacetic Acid as Crth2 Ligands
EP1809326A4 (en) 2004-10-27 2009-11-04 Medimmune Inc MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
WO2008011453A2 (en) * 2006-07-20 2008-01-24 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
EP2064243A2 (en) 2006-08-28 2009-06-03 Kyowa Hakko Kirin Co., Ltd. Antagonistic human light-specific human monoclonal antibodies
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR101686247B1 (ko) 2007-10-31 2016-12-14 메디뮨 엘엘씨 단백질 스캐폴드
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
TWI596113B (zh) 2012-07-25 2017-08-21 塞爾德克斯醫療公司 抗ｋｉｔ抗體及其用途
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
SG11201509982UA (ru) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
EP3041507B1 (en) 2013-08-26 2021-06-30 BioNTech Research and Development, Inc. Nucleic acids encoding human antibodies to sialyl-lewis a
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015271685B2 (en) 2014-06-04 2021-02-18 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
DE112016001013T5 (de) 2015-03-03 2017-12-21 Kymab Limited Antikörper, verwendungen und verfahren
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
WO2018060073A1 (en) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazole derivatives
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102861670B1 (ko) 2017-05-31 2025-09-18 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5681795A (en) * 1994-03-02 1997-10-28 Zeneca Limited 3-benzoyl pyrrole and pyrazole herbicides
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE300298T1 (de) * 1996-03-29 2005-08-15 Therakos Inc Behandlung von leukocyten durch photopheresis
JP2000507597A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼ阻害剤
JP2001509131A (ja) * 1996-04-03 2001-07-10 メルク エンド カンパニー インコーポレーテッド ファルネシルプロテイントランスフェラーゼの阻害剤
AU715658B2 (en) * 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036901A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0904076A1 (en) * 1996-04-03 1999-03-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
IL135473A0 (en) 2001-05-20
EP1045846A1 (en) 2000-10-25
DE69814167T2 (de) 2004-02-26
EP1045846B1 (en) 2003-05-02
ES2193590T3 (es) 2003-11-01
HUP0004238A2 (hu) 2001-05-28
US20020137769A1 (en) 2002-09-26
JP2002161092A (ja) 2002-06-04
AU731272B2 (en) 2001-03-29
AR017700A1 (es) 2001-09-12
NZ504013A (en) 2002-02-01
AU1508399A (en) 1999-06-16
CN1279680A (zh) 2001-01-10
US6268363B1 (en) 2001-07-31
ATE239014T1 (de) 2003-05-15
WO1999028315A1 (en) 1999-06-10
CA2310629A1 (en) 1999-06-10
US6518429B2 (en) 2003-02-11
DE69814167D1 (de) 2003-06-05
CN1188407C (zh) 2005-02-09
JP3548118B2 (ja) 2004-07-28
BR9815423A (pt) 2000-10-17
ID24175A (id) 2000-07-13
US6472526B1 (en) 2002-10-29
HUP0004238A3 (en) 2001-07-30
JP2001524550A (ja) 2001-12-04
PL340729A1 (en) 2001-02-26
RU2179975C1 (ru) 2002-02-27

Similar Documents

Publication Publication Date Title
RU2000116633A (ru) Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, и способ их получения, промежуточные соединения, фармацевтическая композиция
RU2002112227A (ru) Производные пятичленных гетероциклов, способ их получения и их применение в качестве лекарственных средств
FI970825L (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
FR2715847B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
FR2677984B1 (fr) Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
CY2369B1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same.
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
RU2002120504A (ru) Трифторметилпирролкарбоксамиды и трифторметилпирролтиоамиды в качестве фунгицидов
ZA985456B (en) Solid pharmaceutical composition containing benzofuran derivatives.
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
FI964285L (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
PL320916A1 (en) Derivatives of piperasino 2,5-dione as modulators of drug-fastness in respect to amny drugs
FR2681067B1 (fr) Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
ZA93821B (en) New derivatives of baccatin III and of 10-deacetyibaccatin III, their preparation and the pharmaceutical compositions which contain them.
FI970448L (fi) N-substituoituja 3-atsobisyklo(3.2.0)heptaanijohdannaisia,jotka ovat käyttökelpoisia neuroleptisina aineina
AP9801377A0 (en) Tricyclic erythromycin derivatives.
BG103735A (en) Method for the preparation of substituted thiazolidindions
FI945164A7 (fi) Biologisesti aktiivisesti ureidojohdannaiset, jotka ovat käyttökelpoisia antimetastaattisina aineina
AU3430699A (en) Butenolide derivatives as anti-cancer agents
CA2263846A1 (en) Novel pyranoside derivatives
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
FI970449L (fi) N-substituoituja atsabisykloheptaanijohdannaisia, jotka ovat käyttökelpoisia neuroleptisinä aineina

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20061126